These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9240185)

  • 1. Transition zone ratio and prostate-specific antigen density as predictors of the response of benign prostatic hypertrophy to alpha blocker and anti-androgen therapy.
    Kurita Y; Masuda H; Suzuki K; Fujita K; Kawabe K
    Br J Urol; 1997 Jul; 80(1):78-83. PubMed ID: 9240185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transition zone ratio and prostate-specific antigen density: the index of response of benign prostatic hypertrophy to an alpha blocker.
    Kurita Y; Ushiyama T; Suzuki K; Fujita K; Kawabe K
    Int J Urol; 1996 Sep; 3(5):361-6. PubMed ID: 8886912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study.
    Debruyne F; Koch G; Boyle P; Da Silva FC; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP
    Eur Urol; 2002 May; 41(5):497-506; discussion 506-7. PubMed ID: 12074791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study].
    Debruyne F; Koch G; Boyle P; Da Silva FC; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP;
    Prog Urol; 2002 Jun; 12(3):384-92; discussion 394-4. PubMed ID: 12189744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporary intraurethral prostatic bridge-catheter compared with neoadjuvant and adjuvant alpha-blockade to improve early results of high-energy transurethral microwave thermotherapy.
    Djavan B; Ghawidel K; Basharkhah A; Hruby S; Bursa B; Marberger M
    Urology; 1999 Jul; 54(1):73-80. PubMed ID: 10414730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Transition zone index in predicting therapeutic efficacy of benign prostatic hyperplasia].
    Otani T; Fujimoto K; Yoshida K; Ozono S; Hirao Y; Okajima E; Hayashi Y; Kurumatani N
    Nihon Hinyokika Gakkai Zasshi; 2002 Jan; 93(1):20-7. PubMed ID: 11842535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Our experience with the treatment of benign prostatic hyperplasia (BPH) with tamsulosin.
    Cervenakov I; Fillo J
    Bratisl Lek Listy; 2001; 102(3):138-41. PubMed ID: 11433602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A randomized long-term comparative study of clinical efficacy of alpha 1-blocker with or without antiandrogen therapy for benign prostatic hyperplasia: focusing on improvement of I-PSS].
    Ohtani M; Kikuchi K; Tsuchiya A; Noguchi R; Akaza H; Kondo F; Koiso K
    Hinyokika Kiyo; 2000 Nov; 46(11):791-7. PubMed ID: 11193299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or Finasteride.
    Zlotta AR; Teillac P; Raynaud JP; Schulman CC
    Eur Urol; 2005 Aug; 48(2):269-76. PubMed ID: 15939527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical Prostatic Protrusion: A Potential Marker of Alpha-blocker Treatment Success in Patients With Benign Prostatic Enlargement.
    Kalkanli A; Tandogdu Z; Aydin M; Karaca AS; Hazar AI; Balci MB; Aydin M; Nuhoglu B
    Urology; 2016 Feb; 88():161-5. PubMed ID: 26680245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of alpha-blocker response in men with benign prostatic hyperplasia by magnetic resonance imaging.
    Mimata H; Nomura Y; Kasagi Y; Satoh F; Emoto A; Li W; Douno S; Mori H
    Urology; 1999 Nov; 54(5):829-33. PubMed ID: 10565742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transition zone volume and transition zone ratio: predictor of uroflow response to finasteride therapy in benign prostatic hyperplasia patients.
    Tewari A; Shinohara K; Narayan P
    Urology; 1995 Feb; 45(2):258-64; discussion 265. PubMed ID: 7531900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant and adjuvant alpha-blockade improves early results of high-energy transurethral microwave thermotherapy for lower urinary tract symptoms of benign prostatic hyperplasia: a randomized, prospective clinical trial.
    Djavan B; Shariat S; Fakhari M; Ghawidel K; Seitz C; Partin AW; Roehrborn CG; Marberger M
    Urology; 1999 Feb; 53(2):251-9. PubMed ID: 9933035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group.
    Schulman CC; Cortvriend J; Jonas U; Lock TM; Vaage S; Speakman MJ
    Eur Urol; 1996; 29(2):145-54. PubMed ID: 8647140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of interruption of therapy with allylestrenol in patients with benign prostatic hypertrophy.
    Noguchi K; Harada M; Masuda M; Takeda M; Kinoshita Y; Fukushima S; Miyai K; Fukuoka H; Hosaka M
    Int J Urol; 1998 Sep; 5(5):466-70. PubMed ID: 9781436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia.
    Narayan P; Lepor H
    Urology; 2001 Mar; 57(3):466-70. PubMed ID: 11248621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antiandrogen therapy of benign prostatic hypertrophy: clinical effects of allylestrenol evaluated by transrectal ultrasonographic measurement].
    Tsuji Y; Ariyoshi A; Nakamura H; Michinaga S; Tomita Y; Ohmori A; Tahara H; Yamashita Y; Fujisawa Y; Kajiwara I
    Hinyokika Kiyo; 1992 Aug; 38(8):961-6. PubMed ID: 1384295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.